Perioperative and Intensive Care research
A lot of medical research is being done in the Perioperative and Intensive Care units. Our intensive care units carry out, among other things, the international REMAP-CAP pharmacotherapy trial, which is seeking to find appropriate drug therapy from biological antirheumatic drugs for coronavirus patients.
In 2020, 28 new research permits were granted to the Perioperative, Intensive Care and Pain Medicine unit. We are constantly running more than 30 studies.
What are we currently studying?
Read more about our research
REMAP-CAP trial
According to an interim report from the international REMAP-CAP trial, two biologic antirheumatic drugs, tocilizumab and sarilumab, used in combination with cortisone treatment reduce mortality in COVID-19 intensive care patients.
The HUS Intensive Care Unit is studying the treatment of coronavirus disease with two drugs already in use
The HUS Intensive Care Unit is about to begin a pharmacotherapy trial of patients in intensive care due to the coronavirus disease as part of the WHO-sponsored international REMAP-CAP trial.
Updated: 30.07.2025